Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 290

1.

Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.

Shah M, Winfree KB, Peterson P, Gruschkus SK, Eaddy M, Green MR.

Lung Cancer. 2013 Oct;82(1):121-7. doi: 10.1016/j.lungcan.2013.07.021. Epub 2013 Aug 7.

2.

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.

Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desaiah D, Treat JA, Govindan R, Ross HJ.

J Thorac Oncol. 2015 Jan;10(1):134-42. doi: 10.1097/JTO.0000000000000366.

3.

Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.

Klein R, Muehlenbein C, Liepa AM, Babineaux S, Wielage R, Schwartzberg L.

J Thorac Oncol. 2009 Nov;4(11):1404-14. doi: 10.1097/JTO.0b013e3181ba31e0.

4.

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R.

J Clin Oncol. 2013 Dec 1;31(34):4349-57. doi: 10.1200/JCO.2012.47.9626. Epub 2013 Oct 21.

5.

Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.

Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R.

Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310. Review. Erratum in: Health Technol Assess. 2015 May;17(31):281-2.

6.

Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.

Klein R, Wielage R, Muehlenbein C, Liepa AM, Babineaux S, Lawson A, Schwartzberg L.

J Thorac Oncol. 2010 Aug;5(8):1263-72. doi: 10.1097/JTO.0b013e3181e15d16.

7.
8.

A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.

Schuette WH, Gröschel A, Sebastian M, Andreas S, Müller T, Schneller F, Guetz S, Eschbach C, Bohnet S, Leschinger MI, Reck M.

Clin Lung Cancer. 2013 May;14(3):215-23. doi: 10.1016/j.cllc.2012.10.001. Epub 2013 Jan 16.

PMID:
23332288
9.

Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.

Scagliotti GV, Gridelli C, de Marinis F, Thomas M, Dediu M, Pujol JL, Manegold C, San Antonio B, Peterson PM, John W, Chouaki N, Visseren-Grul C, Paz-Ares LG.

Lung Cancer. 2014 Sep;85(3):408-14. doi: 10.1016/j.lungcan.2014.07.005. Epub 2014 Jul 16.

10.

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.

Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ, Smit EF, Ardizzoni A.

Lung Cancer. 2012 Oct;78(1):92-9. doi: 10.1016/j.lungcan.2012.07.009. Epub 2012 Aug 11.

PMID:
22889494
11.

Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non-squamous non-small-cell lung cancer in Spain.

González García J, Gutiérrez Nicolás F, Nazco Casariego GJ, Valcárcel Nazco C, Batista López JN, Oramas Rodríguez J.

Farm Hosp. 2017 Jan 1;41(n01):3-13. doi: 10.7399/fh.2017.41.1.10142.

12.

Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan.

Ahn MJ, Tsai CM, Hsia TC, Wright E, Chang JW, Kim HT, Kim JH, Kang JH, Kim SW, Bae EJ, Kang M, Lister J, Walzer S.

Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:22-33. doi: 10.1111/j.1743-7563.2011.01399.x.

PMID:
21585705
13.

Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.

Reck M, Thatcher N, Smit EF, Lorigan P, Szutowicz-Zielinska E, Liepa AM, Winfree KB, Peterson P, Guba SC, Socinski MA.

Lung Cancer. 2012 Dec;78(3):276-81. doi: 10.1016/j.lungcan.2012.09.002. Epub 2012 Oct 6.

PMID:
23043970
14.

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.

Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, Morando C, Loundou A, Groen HJ, Rittmeyer A.

Ann Oncol. 2014 May;25(5):1044-52. doi: 10.1093/annonc/mdu098. Epub 2014 Feb 27.

PMID:
24585722
15.

Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.

Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni C, Ciuffreda L, Di Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Mattioli R, Cafferata MA, Camisa R, Smit EF.

J Clin Oncol. 2012 Dec 20;30(36):4501-7. doi: 10.1200/JCO.2012.43.6758. Epub 2012 Oct 29.

PMID:
23109689
16.

Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.

Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, Dundar Y, Oyee J, Dickson R, Davis H, Green J, McKenna E, Pearson M.

Health Technol Assess. 2010 Oct;14(Suppl. 2):33-9. doi: 10.3310/hta14suppl2/05. Review.

17.
18.

Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.

Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K, Kaneda T, Yoshimatsu H, Otsuka K, Mio T, Tomioka H, Suzuki Y, Mishima M.

Cancer Chemother Pharmacol. 2012 Aug;70(2):271-6. doi: 10.1007/s00280-012-1910-2. Epub 2012 Jun 30.

PMID:
22752216
19.

Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.

Zinner RG, Novello S, Peng G, Herbst R, Obasaju C, Scagliotti G.

Clin Lung Cancer. 2010 Mar 1;11(2):126-31. doi: 10.3816/CLC.2010.n.017.

PMID:
20199979
20.

An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.

Nuijten MJ, Aultman R, Carpeño Jde C, Vergnenègre A, Chouaid C, Walzer S, Siebert U.

Curr Med Res Opin. 2011 Nov;27(11):2193-201. doi: 10.1185/03007995.2011.626019. Epub 2011 Oct 4.

PMID:
21970659

Supplemental Content

Support Center